Lantern Pharma closed at $0.60 on Nov 3, down 5.89%, within 0.0% of its 52-week closing low. Volume of 187.3K shares was 0.62× its 20-day average (below normal).
Split-adjusted performance: -35.9% over one month, -72.1% over six months, -85.0% over one year.
Short interest was 388.7K shares at the Oct 15 settlement, down 20.0% from the prior report (3.4% of float, 1.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| LTRNLantern Pharma | $0.6023 | −5.89% | −72.1% | — | — | — | $9.0M | |
| INMInMed Pharmaceuticals | $1.68 | +3.07% | +127.0% | — | — | — | $9.2M | Compare |
| PTNPalatin Technologies | $5.22 | +4.61% | −73.9% | — | −1449.1% | — | $9.3M | Compare |
| TPSTTempest Therapeutics | $0.4686 | −0.72% | −78.2% | — | — | — | $9.4M | Compare |
| GTBPGT Biopharma | $5.27 | +2.73% | −44.5% | — | — | — | $9.5M | Compare |
| LEXXLexaria Bioscience | $4.03 | +10.71% | −61.2% | −100.0% | — | — | $8.5M | Compare |
| MBRXMoleculin Biotech | $8.30 | −0.24% | −83.3% | — | — | — | $8.5M | Compare |
| ACTUActuate Therapeutics | $0.3500 | +2.34% | −88.6% | — | — | — | $8.4M | Compare |
| TOVXTheriva Biologics | $0.1820 | −1.09% | −52.1% | — | — | — | $8.4M | Compare |
No recent articles focused on Lantern Pharma.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
